Analysis of clinical characteristics and laboratory examination data of 112 cases of Mycoplasma pneumoniae pneumonia in children
Pingping Wang,Jin Yao,Yaqiong Li,Xiaorong Huang,Chenhui Deng
DOI: https://doi.org/10.1097/md.0000000000040628
IF: 1.6
2024-11-28
Medicine
Abstract:Mycoplasma pneumoniae (MP) is a common pathogen that causes respiratory infections. Mycoplasma pneumoniae pneumonia (MPP) accounts for 10% to 40% of community-acquired pneumonia in children under 18 years old. [ 1 ] MPP usually has mild symptoms and manifests as a self-limited disease. However, in recent years, an increasing number of severe MPP [ 2 , 3 ] and refractory MPP (RMPP) [ 4 ] have emerged in clinical practice, posing great challenges to pediatricians. RMPP is a disease that does not improve after 7 days of treatment with standard macrolide drugs. [ 5 ] Macrolides are the preferred drugs for treating childhood MP infections, but with increasing clinical use, drug resistance issues have become more severe, and RMPP cases are also increasing year by year. [ 6 ] The most common clinical manifestations of MPP include dry cough and fever, usually accompanied by headache, myalgia, sore throat, as well as laboratory tests (mainly elevated inflammatory markers) and abnormal imaging tests (chest computed tomography shows thickening of the bronchial wall, central lobular nodules, lymph node enlargement or ground glass attenuation, etc). [ 7 ] The duration of fever and hospitalization in RMPP is much longer, and the likelihood of developing extrapulmonary complications, including pleural effusion and multiple organ dysfunction, may also lead to more serious long-term sequelae, including obliterative bronchiolitis and bronchiectasis, [ 8 , 9 ] posing a serious threat to the life and health of children. [ 10 ]
medicine, general & internal